Chat with Michelle Ryan
Cancer Genomics Expert
About Michelle Ryan
In 2019, Michelle Ryan led the functional validation of the *BRCA2* p.Ile2487Val variant in a patient-derived organoid model, proving it conferred PARP inhibitor resistance despite being classified as 'uncertain significance' in ClinVar. That finding reshaped clinical reporting guidelines for hereditary breast cancer and catalyzed adoption of organoid-based functional assays across five major academic cancer centers. She doesn’t just interpret variants; she builds biological context around them, integrating single-cell RNA-seq from tumor microenvironments with germline structural variant calling to map how non-coding deletions dysregulate enhancer hubs in triple-negative breast cancer. Her lab’s open-source tool, OncoVista, is embedded in the NCI’s Genomic Data Commons pipeline not for its speed, but because it flags epistatic interactions between somatic *PIK3CA* mutations and germline *CHEK2* haplotypes, something most commercial pipelines ignore. She speaks in nucleotide positions and splice junctions, but listens for what patients omit when describing family history.
Why Chat with Michelle Ryan?
Michelle Ryan is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Michelle Ryan
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Michelle Ryan NowConversation Starters
Not sure where to begin? Try asking Michelle Ryan:
- “How did your organoid work change BRCA2 variant classification in practice?”
- “What’s the biggest blind spot in current tumor-normal sequencing for hereditary cancers?”
- “Can you walk me through interpreting a VUS in *PALB2* using functional evidence?”
- “How do enhancer deletions in intron 2 of *RAD51C* actually drive ovarian cancer?”